Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT

Persistent Asset Partners Ltd purchased a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 145,585 shares of the company’s stock, valued at approximately $1,936,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its position in shares of 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after acquiring an additional 2,882,508 shares during the period. State Street Corp raised its holdings in 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after purchasing an additional 1,785,106 shares during the period. RA Capital Management L.P. increased its holdings in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after acquiring an additional 1,090,000 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock worth $9,264,000 after acquiring an additional 1,060,156 shares during the period. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in 4D Molecular Therapeutics during the fourth quarter worth $7,136,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on FDMT. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. B. Riley Financial began coverage on 4D Molecular Therapeutics in a research note on Friday, July 31st. They issued a “buy” rating and a $37.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.62.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $12.19 on Monday. 4D Molecular Therapeutics, Inc. has a one year low of $5.97 and a one year high of $14.00. The company has a market cap of $637.29 million, a price-to-earnings ratio of -4.63 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The business’s 50 day moving average price is $10.94 and its 200 day moving average price is $9.89.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. On average, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current year.

Insider Activity

In related news, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 197,226 shares of company stock worth $2,200,677. Corporate insiders own 7.90% of the company’s stock.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.